Literature DB >> 18596162

Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components.

Ying-Jiun J Chen1, Madeleine A Johnson, Michael D Lieberman, Rose E Goodchild, Scott Schobel, Nicole Lewandowski, Gorazd Rosoklija, Ruei-Che Liu, Jay A Gingrich, Scott Small, Holly Moore, Andrew J Dwork, David A Talmage, Lorna W Role.   

Abstract

Neuregulin-1 (Nrg1)/erbB signaling regulates neuronal development, migration, myelination, and synaptic maintenance. The Nrg1 gene is a schizophrenia susceptibility gene. To understand the contribution of Nrg1 signaling to adult brain structure and behaviors, we studied the regulation of type III Nrg1 expression and evaluated the effect of decreased expression of the type III Nrg1 isoforms. Type III Nrg1 is transcribed by a promoter distinct from those for other Nrg1 isoforms and, in the adult brain, is expressed in the medial prefrontal cortex, ventral hippocampus, and ventral subiculum, regions involved in the regulation of sensorimotor gating and short-term memory. Adult heterozygous mutant mice with a targeted disruption for type III Nrg1 (Nrg1(tm1.1Lwr+/-)) have enlarged lateral ventricles and decreased dendritic spine density on subicular pyramidal neurons. Magnetic resonance imaging of type III Nrg1 heterozygous mice revealed hypofunction in the medial prefrontal cortex and the hippocampal CA1 and subiculum regions. Type III Nrg1 heterozygous mice also have impaired performance on delayed alternation memory tasks, and deficits in prepulse inhibition (PPI). Chronic nicotine treatment eliminated differences in PPI between type III Nrg1 heterozygous mice and their wild-type littermates. Our findings demonstrate a role of type III Nrg1 signaling in the maintenance of corticostriatal components and in the neural circuits involved in sensorimotor gating and short-term memory.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596162      PMCID: PMC2728592          DOI: 10.1523/JNEUROSCI.1815-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  104 in total

Review 1.  The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia.

Authors:  P S Goldman-Rakic
Journal:  Biol Psychiatry       Date:  1999-09-01       Impact factor: 13.382

2.  Dendritic spine changes associated with hippocampal long-term synaptic plasticity.

Authors:  F Engert; T Bonhoeffer
Journal:  Nature       Date:  1999-05-06       Impact factor: 49.962

3.  Receptor tyrosine kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain.

Authors:  E S Anton; H T Ghashghaei; Janet L Weber; Corey McCann; Tobias M Fischer; Isla D Cheung; Martin Gassmann; Albee Messing; Rudiger Klein; Markus H Schwab; K C Kent Lloyd; Cary Lai
Journal:  Nat Neurosci       Date:  2004-11-07       Impact factor: 24.884

4.  Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans.

Authors:  Takatoshi Hikida; Hanna Jaaro-Peled; Saurav Seshadri; Kenichi Oishi; Caroline Hookway; Stephanie Kong; Di Wu; Rong Xue; Manuella Andradé; Stephanie Tankou; Susumu Mori; Michela Gallagher; Koko Ishizuka; Mikhail Pletnikov; Satoshi Kida; Akira Sawa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-03       Impact factor: 11.205

Review 5.  Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates.

Authors:  Jeffrey W Dalley; Rudolf N Cardinal; Trevor W Robbins
Journal:  Neurosci Biobehav Rev       Date:  2004-11       Impact factor: 8.989

6.  Neurobiology: new order for thought disorders.

Authors:  Lorna W Role; David A Talmage
Journal:  Nature       Date:  2007-07-19       Impact factor: 49.962

7.  Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex.

Authors:  Zhenglin Gu; Qian Jiang; Amy K Y Fu; Nancy Y Ip; Zhen Yan
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

8.  Multiple novel transcription initiation sites for NRG1.

Authors:  Valgerdur Steinthorsdottir; Hreinn Stefansson; Shyamali Ghosh; Birgitta Birgisdottir; Soley Bjornsdottir; Anne Charlotte Fasquel; Olafur Olafsson; Kari Stefansson; Jeffrey R Gulcher
Journal:  Gene       Date:  2004-11-10       Impact factor: 3.688

9.  Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition.

Authors:  Mendell Rimer; Douglas W Barrett; Monica A Maldonado; Vita M Vock; F Gonzalez-Lima
Journal:  Neuroreport       Date:  2005-02-28       Impact factor: 1.837

10.  Neuregulin-1beta induces neurite extension and arborization in cultured hippocampal neurons.

Authors:  Kimberly M Gerecke; J Michael Wyss; Steven L Carroll
Journal:  Mol Cell Neurosci       Date:  2004-12       Impact factor: 4.314

View more
  92 in total

1.  Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice.

Authors:  Malcolm W Nason; Avishek Adhikari; Marjan Bozinoski; Joshua A Gordon; Lorna W Role
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

Review 2.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 3.  Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development.

Authors:  Christina Wilson; Alvin V Terry
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-07

Review 4.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

5.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

6.  Sex-specific neuroendocrine and behavioral phenotypes in hypomorphic Type II Neuregulin 1 rats.

Authors:  Sara B Taylor; Julie A Markham; Adam R Taylor; Brooke Z Kanaskie; James I Koenig
Journal:  Behav Brain Res       Date:  2011-05-19       Impact factor: 3.332

Review 7.  Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway.

Authors:  Chao Deng; Bo Pan; Martin Engel; Xu-Feng Huang
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 8.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

Review 9.  Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models.

Authors:  Hanna Jaaro-Peled; Yavuz Ayhan; Mikhail V Pletnikov; Akira Sawa
Journal:  Schizophr Bull       Date:  2009-11-10       Impact factor: 9.306

10.  Reversal of behavioral deficits and synaptic dysfunction in mice overexpressing neuregulin 1.

Authors:  Dong-Min Yin; Yong-Jun Chen; Yi-Sheng Lu; Jonathan C Bean; Anupama Sathyamurthy; Chengyong Shen; Xihui Liu; Thiri W Lin; Clifford A Smith; Wen-Cheng Xiong; Lin Mei
Journal:  Neuron       Date:  2013-05-22       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.